Whole-Body but Not Hepatic Knockdown of Chemerin by Antisense Oligonucleotide Decreases Blood Pressure in Rats

The Journal of Pharmacology and Experimental Therapeutics
David J FerlandStephanie W Watts

Abstract

Chemerin is an inflammatory adipokine positively associated with hypertension and obesity. The majority of chemerin derives from the liver and adipose tissue, however, their individual contributions to blood pressure are unknown. We began studying chemerin in the normal rat using antisense oligonucleotides (ASO) with whole-body activity (Gen 2.5 chemerin ASO) or liver-restricted activity (GalNAc chemerin ASO). We hypothesized that in normotensive male Sprague-Dawley rats, circulating chemerin is predominately liver-derived and regulates blood pressure. A dosing study of the Gen 2.5 chemerin ASO (with a scrambled control ASO) supported 25 mg/kg as the appropriate dose. GalNAc chemerin ASO was also assessed and used at 10 mg/kg. Radiotelemetry monitored mean arterial pressure (MAP) for a 1-week baseline and weekly subcutaneous ASO injections for 4 weeks. Two days after the final injection, animals were euthanized for tissue reverse transcription-polymerase chain reaction and chemerin Western analysis. Gen 2.5 chemerin ASO treatments reduced chemerin mRNA and protein in liver, retroperitoneal fat (RP), and mesenteric perivascular adipose tissue (mPVAT), as well as reducing protein in plasma. GalNAc chemerin ASO treatments reduced ...Continue Reading

References

Sep 5, 2001·Kidney International·S T MorrisA G Jardine
Oct 8, 2003·The Journal of Experimental Medicine·Valérie WittamerDavid Communi
Dec 22, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Brian A ZabelEugene C Butcher
Mar 2, 2005·Trends in Microbiology·Mariella Della ChiesaAlessandro Moretta
Jul 20, 2007·The Journal of Biological Chemistry·Kerry B GoralskiChristopher J Sinal
Jul 21, 2007·Endocrinology·Kiymet BozaogluDavid Segal
Dec 31, 2008·The Journal of Experimental Medicine·Cristina AlbanesiSilvano Sozzani
Mar 20, 2010·The Journal of Clinical Endocrinology and Metabolism·Kiymet BozaogluJeremy B M Jowett
Dec 6, 2011·Metabolism: Clinical and Experimental·Rima ChakarounMatthias Blüher
Apr 6, 2013·Arteriosclerosis, Thrombosis, and Vascular Biology·Stephanie W WattsGregory D Fink
Mar 15, 2015·Circulation Research·John E HallMichael E Hall
Apr 12, 2016·Cellular & Molecular Immunology·Mark W RobinsonCliona O'Farrelly
Jul 3, 2016·American Journal of Physiology. Heart and Circulatory Physiology·Emma S DariosStephanie W Watts
Oct 13, 2016·Annual Review of Pharmacology and Toxicology·C Frank BennettRichard S Geary
Nov 29, 2016·Vascular Pharmacology·David J FerlandStephanie W Watts

❮ Previous
Next ❯

Citations

May 27, 2020·American Journal of Hypertension·David J FerlandStephanie W Watts
Mar 8, 2019·International Journal of Molecular Sciences·Christa BuechlerCharalampos Aslanidis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.